Famotidine

Generic Name: Famotidine

Brand Names: Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₅N_₇O_₂S_₃

CAS Number: 76824-35-6

Unique Ingredient Identifier: 5QZO15J2Z8

Background: Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity to...

Indication: Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.
...

Associated Conditions: Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions

Associated Therapies: -

Clinical Trials

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Remdesivir
Drug: Imatinib Mesylate
Drug: Dexamethasone
Biological: dornase alfa
Drug: Celecoxib
Biological: IC14
Biological: narsoplimab
Drug: Cenicriviroc
Drug: Apremilast
Drug: Icatibant
Drug: Aviptadil
Drug: Cyproheptadine
Drug: Cyclosporine
Drug: Famotidine

First Posted Date: 2020-07-27

Last Posted Date: 2024-03-19

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 1500

Registration Number: NCT04488081

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 33 locations

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Famotidine

First Posted Date: 2020-07-14

Last Posted Date: 2022-01-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT04470778

Locations: 🇺🇸
ICON (PRA Health Sciences) - Salt Lake, Salt Lake City, Utah, United States

A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: JNJ-64417184
Drug: Lansoprazole
Drug: Famotidine

First Posted Date: 2020-07-01

Last Posted Date: 2020-11-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT04453189

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

Histamine H1/H2 Receptors and Training Adaptations

Not Applicable

Completed

Conditions: Exercise Training
Physical Activity

Interventions: Other: Lactose
Drug: Fexofenadine Hydrochloride
Other: High-intensity interval training (HIIT)
Drug: Famotidine

First Posted Date: 2020-06-29

Last Posted Date: 2024-06-07

Lead Sponsor: University Ghent

Target Recruit Count: 19

Registration Number: NCT04450134

Locations: 🇧🇪
Department of Movement and Sports Sciences, Ghent University, Gent, Oost-Vlaanderen, Belgium

Famotidine Outpatient COVID-19 Treatment Study

Completed

Conditions: COVID-19

Interventions: Drug: Famotidine

First Posted Date: 2020-05-15

Last Posted Date: 2023-05-06

Lead Sponsor: Northwell Health

Target Recruit Count: 10

Registration Number: NCT04389567

Locations: 🇺🇸
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Daridorexant
Drug: Efavirenz
Drug: Famotidine

First Posted Date: 2020-05-15

Last Posted Date: 2020-09-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT04390334

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Phase 2

Recruiting

Conditions: Gastric Cancer
Stomach Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Palonosetron
Radiation: 3D conformal or intensity modulated radiotherapy
Procedure: Surgical resection
Radiation: Adjuvant Chemotherapy

First Posted Date: 2020-03-16

Last Posted Date: 2023-11-14

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 29

Registration Number: NCT04308837

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Mount Sinai St. Luke's, New York, New York, United States
🇺🇸
Mount Sinai West, New York, New York, United States